Nature Communications (Feb 2021)

Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

  • Alan Bénard,
  • Anne Jacobsen,
  • Maximilian Brunner,
  • Christian Krautz,
  • Bettina Klösch,
  • Izabela Swierzy,
  • Elisabeth Naschberger,
  • Malgorzata J. Podolska,
  • Dina Kouhestani,
  • Paul David,
  • Torsten Birkholz,
  • Ixchel Castellanos,
  • Denis Trufa,
  • Horia Sirbu,
  • Marcel Vetter,
  • Andreas E. Kremer,
  • Kai Hildner,
  • Andreas Hecker,
  • Fabian Edinger,
  • Matthias Tenbusch,
  • Petra Mühl-Zürbes,
  • Alexander Steinkasserer,
  • Enrico Richter,
  • Hendrik Streeck,
  • Marc M. Berger,
  • Thorsten Brenner,
  • Markus A. Weigand,
  • Filip K. Swirski,
  • Georg Schett,
  • Robert Grützmann,
  • Georg F. Weber

DOI
https://doi.org/10.1038/s41467-021-21310-4
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 8

Abstract

Read online

Here, the authors identify interleukin-3 as a predictive marker for severity and outcome of SARS-CoV-2 infection in a multi-center, prospective study and find that patients with severe COVID-19 have reduced circulating plasmacytoid dendritic cell levels compared to non-severe COVID-19 patients.